Literature DB >> 8916167

Rhabdomyolysis and anesthesia: a report of two cases and review of the literature.

N E Pedrozzi1, G P Ramelli, R Tomasetti, L Nobile-Buetti, M G Bianchetti.   

Abstract

Rhabdomyolysis occurred in two apparently healthy boys aged 9.5 and 5.5 years after general anesthesia with suxamethonium. Mild hyperkalemia and renal failure were observed in the first patient, who was subsequently diagnosed with Becker dystrophy. In the second patient, the clinical presentation was not classic for malignant hyperthermia and a muscle biopsy failed to disclose any pathological finding. A review of the literature revealed 66 pediatric cases (56 boys and 10 girls) of anesthesia-associated rhabdomyolysis. Forty-nine (74%) cases were caused by an underlying, mostly unrecognized congenital muscle disease, and 14 (21%) cases were caused by malignant hyperthermia susceptibility. Hyperkalemia (23 patients), cardiac arrhythmias (38 patients), renal failure (4 patients), and death (11 patients) were the most serious complications of anesthesia-associated rhabdomyolysis. The neuromuscular blocking agent suxamethonium had been used in at least 43 of the patients reported in the literature.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8916167     DOI: 10.1016/s0887-8994(96)00171-3

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  3 in total

1.  Orthodontic treatment in a patient with unilateral open-bite and Becker muscular dystrophy. A 5-year follow-up.

Authors:  Juan Fernando Aristizabal; Rosana Martínez Smit
Journal:  Dental Press J Orthod       Date:  2014-12-01

2.  Ventricular fibrillation and rhabdomyolysis after administration of succinylcholine.

Authors:  R L Braam; J K J Deegens; H J G Jessen; A J M Oude Ophuis; B T J Meursing
Journal:  Neth Heart J       Date:  2003-12       Impact factor: 2.380

3.  Rhabdomyolysis updated.

Authors:  G Efstratiadis; A Voulgaridou; D Nikiforou; A Kyventidis; E Kourkouni; G Vergoulas
Journal:  Hippokratia       Date:  2007-07       Impact factor: 0.471

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.